genOway Opens Its First Franchises in Canada and Australia to Accelerate International Expansion
genOway announces the opening of its first two distribution franchises in Canada and Australia, marking a key milestone in its strategic plan ROUTE50+DATA. This initiative is part of the group's international business strategy aimed at expanding its presence in significant biopharmaceutical markets.
genOway continues its international expansion by establishing a model of 'genOway Franchises' entrusted to local entrepreneurs. Canada and Australia are hosting the first two franchises, with the ambition to rapidly increase sales. These franchises will initially capitalize on a base of historical clients before penetrating the main bioclusters of these markets. The first sales from these distribution contracts are expected as early as the third quarter of 2026. The genOway Franchise network is expected to contribute around 15% of revenues by 2028.
Expansion of the Franchise Network within a Broader Commercial Strategy
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The development of the franchise network is part of a broader commercial plan. genOway is strengthening its sales teams in its priority markets (United States and major European countries) and is establishing new commercial subsidiaries to address large Asian markets (China, Japan, and India). This model is based on the strategic choice to rely on about ten distribution agreements tested over the past five years. The franchisees, equipped with a strong scientific background and deep market knowledge, will ensure the exclusive distribution of genOway's preclinical solutions.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Context
Period
Period: 2025
Guidance from the release
L’année 2025 constitue une année de construction pour genOway.
Visibilité sur le 1er semestre 2026; croissance organique >10% en 2026; ROUTE50+ et ROUTE50+DATA; acquisition BIOASTER; perspectives positives sur rentabilité et croissance.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
